Skip to main content
GutCited

Quy trình nghiên cứu

477 hình ảnh từ nghiên cứu có bình duyệt

Tất cả Psyllium Husk Bifidobacterium lactis Fructooligosaccharides (FOS) Lactobacillus plantarum Peppermint Oil Pancreatic Enzymes (Pancrelipase) Curcumin Vitamin A Medium-Chain Triglycerides (MCT Oil) Galactooligosaccharides (GOS) Lactobacillus gasseri Aloe Vera (Inner Leaf Gel) Alpha-Galactosidase Vitamin D L-Glutamine Inulin Ginger Lactase Berberine Omega-3 Fatty Acids (EPA/DHA) Bovine Colostrum Zinc Bifidobacterium bifidum Butyrate (Sodium/Calcium Butyrate) Bacillus coagulans Saccharomyces boulardii Lactobacillus acidophilus N-Acetyl Cysteine (NAC) Bifidobacterium longum
All Types Chart Diagram Photograph Flowchart Forest Plot Micrograph Other
Figure 8
Figure 8 Diagram

Evidence summary for S. boulardii CNCM I-745 efficacy against specific intestinal pathogens including Clostridium difficile, showing toxin neutralization and receptor binding inhibition mechanisms.

Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.

Figure 9
Figure 9 Diagram

Overview of enzymatic activities of S. boulardii relevant to intestinal infection defense, including protease secretion that degrades bacterial toxins and virulence factors.

Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.

Figure 10
Figure 10 Diagram

Overview of enzymatic activities of S. boulardii relevant to intestinal infection defense, including protease secretion that degrades bacterial toxins and virulence factors.

Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.

Figure 5
Figure 5 Diagram

Clinical applications of S. boulardii across various gastrointestinal conditions are summarized, reflecting its established effectiveness in acute diarrhea treatment and prevention.

Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system.

Figure 6
Figure 6 Diagram

A comprehensive model of S. boulardii's multifaceted interactions with host immunity and intestinal microbiota is presented, integrating molecular and clinical evidence.

Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system.

Fig. 2. Gel-like images of the lentil protein sources under non-reducing and reducing conditions obtained from Bioanalyzer using an Agilent 80 + protein chip.
Figure 3 Micrograph

Gel-like electrophoresis images compare the protein molecular weight distribution of lentil protein sources under reducing and non-reducing conditions, revealing the impact of processing methods on protein subunit composition.

Nutritional and anti-nutritional properties of lentil (Lens culinaris) protein isolates prepared by …

Figure 1
Figure 1

Summary of systematic review findings on over-the-counter therapies for chronic constipation, synthesizing evidence from randomized controlled trials evaluating fiber supplements, osmotic laxatives, and stimulant laxatives.

Efficacy and Safety of Over-the-Counter Therapies for Chronic Constipation: An Updated Systematic …

Figure 3
Figure 3 Chart

In vitro or in vivo efficacy data for the inulin hydrogel system, evaluating anti-inflammatory and anti-fibrotic effects in intestinal tissue models.

Ternary inulin hydrogel with long-term intestinal retention for simultaneously reversing IBD and …

Figure 4
Figure 4 Chart

In vitro or in vivo efficacy data for the inulin hydrogel system, evaluating anti-inflammatory and anti-fibrotic effects in intestinal tissue models.

Ternary inulin hydrogel with long-term intestinal retention for simultaneously reversing IBD and …

Figure 5
Figure 5 Chart

In vitro or in vivo efficacy data for the inulin hydrogel system, evaluating anti-inflammatory and anti-fibrotic effects in intestinal tissue models.

Ternary inulin hydrogel with long-term intestinal retention for simultaneously reversing IBD and …

Figure 6
Figure 6 Chart

Therapeutic outcome measurements from the DSS-induced colitis model treated with the inulin hydrogel, assessing colon histology, inflammatory markers, and fibrosis resolution.

Ternary inulin hydrogel with long-term intestinal retention for simultaneously reversing IBD and …

Figure 10
Figure 10 Chart

Intestinal microbiome restoration data following inulin hydrogel treatment, showing probiotic-mediated recovery of microbial diversity and beneficial bacterial populations.

Ternary inulin hydrogel with long-term intestinal retention for simultaneously reversing IBD and …

Figure 11
Figure 11 Chart

Supplementary characterization or mechanistic data from the ternary inulin hydrogel study, providing additional evidence for the dual anti-inflammatory and anti-fibrotic therapeutic approach.

Ternary inulin hydrogel with long-term intestinal retention for simultaneously reversing IBD and …

Figure 12
Figure 12 Chart

Supplementary characterization or mechanistic data from the ternary inulin hydrogel study, providing additional evidence for the dual anti-inflammatory and anti-fibrotic therapeutic approach.

Ternary inulin hydrogel with long-term intestinal retention for simultaneously reversing IBD and …

Figure 13
Figure 13 Chart

Supplementary characterization or mechanistic data from the ternary inulin hydrogel study, providing additional evidence for the dual anti-inflammatory and anti-fibrotic therapeutic approach.

Ternary inulin hydrogel with long-term intestinal retention for simultaneously reversing IBD and …

Figure 14
Figure 14 Chart

Supplementary characterization or mechanistic data from the ternary inulin hydrogel study, providing additional evidence for the dual anti-inflammatory and anti-fibrotic therapeutic approach.

Ternary inulin hydrogel with long-term intestinal retention for simultaneously reversing IBD and …

Figure 15
Figure 15 Chart

Supplementary characterization or mechanistic data from the ternary inulin hydrogel study, providing additional evidence for the dual anti-inflammatory and anti-fibrotic therapeutic approach.

Ternary inulin hydrogel with long-term intestinal retention for simultaneously reversing IBD and …

Figure 3
Figure 3 Diagram

Mechanistic diagram illustrating the role of ferroptosis — characterized by iron accumulation, lipid peroxidation, and ROS production — in the pathogenesis of inflammatory bowel disease and its potential as a therapeutic target.

Role of ferroptosis in the pathogenesis and as a therapeutic target of …

Figure 4
Figure 4 Diagram

Mechanistic diagram illustrating the role of ferroptosis — characterized by iron accumulation, lipid peroxidation, and ROS production — in the pathogenesis of inflammatory bowel disease and its potential as a therapeutic target.

Role of ferroptosis in the pathogenesis and as a therapeutic target of …

Figure 5
Figure 5 Diagram

Mechanistic diagram illustrating the role of ferroptosis — characterized by iron accumulation, lipid peroxidation, and ROS production — in the pathogenesis of inflammatory bowel disease and its potential as a therapeutic target.

Role of ferroptosis in the pathogenesis and as a therapeutic target of …

Figure 6
Figure 6 Diagram

Mechanistic diagram illustrating the role of ferroptosis — characterized by iron accumulation, lipid peroxidation, and ROS production — in the pathogenesis of inflammatory bowel disease and its potential as a therapeutic target.

Role of ferroptosis in the pathogenesis and as a therapeutic target of …

Figure 1 Epithelial mechanisms of vitamin D: (1) increased VDR activity is shown to repress NF-κB-dependent epithelial apoptosis pathways in experimental colitis. (2) Claudin-2 (CL-2), a paracellular cation channel involved in barrier formation, seems to
Figure 1 Diagram

Epithelial mechanisms of vitamin D in IBD, illustrating VDR-mediated NF-kB suppression, claudin-2 regulation at the paracellular barrier, and other pathways through which vitamin D influences intestinal inflammation.

Managing vitamin D deficiency in inflammatory bowel disease.

Figure 2 Approach to 25(OH)D supplementation in patients with IBD. Determining adequate daily dose as (target s-25(OH)D level – current s-25(OH)D level) µg. If target level is not reached within 3 months, administration as weekly bolus should be tried. If
Figure 2 Flowchart

Clinical algorithm for vitamin D supplementation in IBD patients, showing dose calculation based on target 25(OH)D levels, escalation to weekly bolus if targets are unmet, and malabsorption workup considerations.

Managing vitamin D deficiency in inflammatory bowel disease.

Figure 24
Figure 24 Diagram

Supplementary qualitative analysis details the range of symptom severity and frequency reported by PEI patients during structured interviews.

Qualitative Assessment of the Symptoms and Impact of Pancreatic Exocrine Insufficiency (PEI) …

Trang 7 / 20